The disruptive elements of the U.S. Stargate program and the release of the Chinese artificial-intelligence company DeepSeek has put more critical eyes than ever on major AI players like Microsoft ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

In a remarkable display of market confidence, HIMS & Hers Health, Inc. (HIMS) stock has soared to an all-time high, reaching ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Danone's shares have fallen by 13% over five years, but the company has improved significantly, increasing revenues and free ...

Chevron's board has raised the energy giant's quarterly dividend by 4.9%, to $1.71 from $1.63. The new payout, equal to $6.84 a year, represents an annual yield of about 4.38% based on Thursday's ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Ltd. (BABA), ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.